AstraZeneca
promising efficacy in heavily treated patients with ovarian breast and endometrial cancer sie | AstraZeneca
Company
Deck Type
Sector
Industry
Deck date
September 2024
Slide
41 of 55
Related slides by other companies
Kymera
Investor Presentation
August 2023
overall safety | Kymera
Nuvalent
Investor Presentation
August 2023
preliminary efficacy radiographic tumor regression observed across all dose levels | Nuvalent
Nuvalent
Investor Presentation
October 2022
preliminary efficacy radiographic tumor regression observed across all dose levels | Nuvalent
Kymera
Investor Presentation
June 2023
overall safety | Kymera
Other recent decks by AstraZeneca
See all presentations (31 decks)
Results
February 2025
Results
November 2024
Results
November 2024
Results
February 2024
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights